Advaxis — Investor Presentation (February 2019)
11 slides from Advaxis's investor presentation, Feb 7, 2019
Slide 1: Lm-Based Immunotherapies: Leveraging the Advantages of a Unique Vector to Attack Cancer
IMMUNOTHERAPIES™ Lm-Based Immunotherapies: Leveraging.the ~ Advantages of a Unique Vector to,Attack Cancer. ~ Chief Scientific Officer Advaxis,-Inc: Chief Medical Offices Advaxis, Inc®®
Slide 2: Advaxis Overview
Advaxis Overview + Listeria monocytogenes (Lm): Bacterial vector optimized to deliver large antigen payloads directly inside dendritic/antigen presenting cells + Ability to generate CD8+T cells rapidly and against large percentage of peptide/neoantigen targets = > 90% in pre-clinical studies * Preli
Slide 3: Anti-Tumor Immunity: Building Blocks for Clinical Success
Anti-Tumor Immunity: Building Blocks for Clinical Success IMMUNOTHERAPIES Induction of y YY fee / Vaccine. v4 cripheral Priming of V\ / ‘col induced / Promote { eee ] { T cell ) | tumors into | T cells { antigen response “hot” } infiltrate to spreading / \. responses \ tumors y the tumor _/ ‘X \ y q
Slide 4: Best-in-Class Potential in Neoantigen Field
Best-in-Class Potential in Neoantigen Field Advaxis neoantigen programs leverage our Lm vector’s capacity for : ELISPOT data large number of antigens ‘ADXS-NEO - ADXS-NEO constructs currently utilize 40 private neoantigens per patient MSS-CRC patient » ADXS-HOT constructs utilize > 30 public hotspot
Slide 5: HPV: Vaccine Expressing HPV (tLLO-E7)
HPV: Vaccine Expressing HPV 16 (tLLO-E7) ADXS-HPV (AXAL) Clinical data: Prolonged survival and complete responses in cervical and anal cancer subjects and antigen spreading observed + Mostly Grade 1-2 (mild-moderate) chills, pyrexia, nausea, fatigue, headache and hypotension, shortly after infusion
Slide 6: AXAL Phase AIM2CERV — Registration Trial
AXAL Phase 3 AIM2CERV — Registration Trial’ ee Study Design Total no. patients = 450 neterenee Primary Endpoint: ore [ser] * Disease-free survival 4 Secondary Outcome Measures: + Safety & Tolerability Cisplatin (at east = Overall survival ‘uk exposure) ‘snd Rewiowon = = Patient reported outcomes (mi
Slide 7: ADXS-PSA + Pembrolizumab in Metastatic Castration Resistant Prostate Cancer
ADXS-PSA + Pembrolizumab in Metastatic Castration Resistant Prostate Cancer ADXS-PSA . ' 50* subjects, predominantly bone disease only Part A (ADXS-PSA monotherapy; N=13) in Clinical evidence of Part B (ADXS-PSA + pembrolizumab; N=37) seuinoraters © merci disease stabilization and a . anligen saroad
Slide 8: ADXS-NEO: Personalized Neoantigen Vaccine
ADXS-NEO: Personalized Neoantigen Vaccine ADXS-NEO Part A ‘ADXS-NEO Monotherapy Dose Escalation / Dose De-Escalation 343 Design Personalized, patient-specific candidates based on sequencing of each subject's tumor Endpoints: Primary Tolerabilty/ Safety Part B ‘ADXS-NEO + anti-PD-1 antibody Dose Esca
Slide 9: ADXS-HOT (503): NSCLC-Specific Vaccine
ADXS-HOT (503): NSCLC-Specific Vaccine ADXS-HOT Part Part B Part C ADXS-503 Monotherapy Dose Escalation ADXS-503 + anti-PD-1 antibody ‘ADXS-503 + anti-PD-1 antibody Cancer type-speci 343 Design Dose Escalation 343 Design candidates based on commonly expressed public hotspot mutations and proprietary
Slide 10: Next-Generation Cancer Immunotherapies Using a Proprietary Lm Platform
Next-Generation Cancer Immunotherapies Using a Proprietary Lm Platform e Leveraging unique properties of Lm vector = Capable of delivering large antigen payloads directly inside dendritic/antigen presenting cells ¢ Broad pipeline of drug candidates for multiple cancer types = From Phase 1 to Phase 3
Slide 11: References
References on Wood L, Paterson Y. Front Cell Infect Microbiol. 2014:4:51 Coder B. Targeting shared hotspot cancer mutations with a Listeria monocytogenes immunotherapy induce potent anti-tumor immunity. Poster Presentation, AACR 2018. Manuscript in preparation. Coder B. Neoantigens that fail to elic